Rosalind Advisors, Inc. - 13 Feb 2025 SCHEDULE 13G/A Report for Trevi Therapeutics, Inc. Common Shares (TRVI)

Filing Manager
Rosalind Advisors, Inc.
Reporting Manager
Rosalind Advisors, Inc.
Security
Trevi Therapeutics, Inc. Common Shares
Symbol
TRVI
Shares outstanding
88,541,667 shares
Disclosed Ownership
1,062,500 shares
Ownership
1.2%
Form type
SCHEDULE 13G/A
Filing time
13 Feb 2025, 13:41:23 UTC
Date of event
13 Feb 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Rosalind Advisors, Inc. disclosed 1.2% ownership in Trevi Therapeutics, Inc. Common Shares (TRVI) on 13 Feb 2025."

Quick Takeaways

  • Rosalind Advisors, Inc. filed SCHEDULE 13G/A for Trevi Therapeutics, Inc. Common Shares (TRVI).
  • Disclosed ownership: 1.2%.
  • Date of event: 13 Feb 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Feb 2025, 13:41.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Rosalind Advisors, Inc. 1.2% 1,062,500 0 1,062,500 Steven Salamon President
SALAMON STEVEN A J 1.2% 1,062,500 0 1,062,500 Steven Salamon Steven Salamon
Aharon Gil 1.2% 1,062,500 0 1,062,500 Gil Aharon Gil Aharon
Rosalind Master Fund L.P. 1.2% 1,062,500 0 1,062,500 Mike McDonald Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

Sponsored